Cardiovascular disease and risk factors in patients with type 2 diabetes mellitus in Mashhad, Islamic Republic of Iran;Maladies cardio-vasculaires et facteurs de risque chez des patients atteints de diabète de type 2 à Mashhad (République Islamique d'Iran)

Eastern Mediterranean Health Journal

Volumn 17, Issue 9, 2011, Pages 640-646

  Bonakdaran, S ^a   Ebrahimzadeh, S ^a   Noghabi, S H ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; HUMAN; HYPERTENSION; IRAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK FACTOR;

EID: 80052753082     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2011.17.9.640     Document Type: Article

References (36)

1. Stirban AO, Tschoepe D. Cardiovascular complications in diabetes: targets and interventions. Diabetes Care, 2008, 31(Suppl. 2):S215-S217.
2. Grundy SM et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 2004, 110:227-239.
3. Lu W et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care, 2003, 26:16-23.
4. Kalaitzidis R, Bakris G. Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. Diabetes, Obesity and Metabolism, 2009, 11:757-769.
5. Khalangot M et al. Body mass index and the risk of total and cardiovascular mortality among patients with type 2 diabetes: a large prospective study in Ukraine. Heart, 2009, 95:454-460.
6. Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and the endothelium. American Journal of Medicine, 2004, 117:109-117.
7. Yokoyama H et al. Reduced GFR and microalbuminuria are independently associated with prevalent cardiovascular disease in type 2 diabetes: JDDM study 16. Diabetic Medicine, 2008, 25:1426-1432.
8. Popovic-Pejicic S, Todorovic-Dilas L, Pantelinac P. [The role of autonomic cardiovascular neuropathy in pathogenesis of ischemic heart disease in patients with diabetes mellitus]. Medicinski Pregled, 2006, 59:118-123 [in Serbian].
9. Sahli D et al. Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes. Thrombosis Research, 2009, 123:701-706.
10. Mazzone T. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention. American Journal of Medicine, 2007, 120(Suppl. 2):S26-S32.
11. UKPDS Risk Engine. Oxford Centre for Diabetes, Endocrinology and Metabolism [website] (www.dtu.ox.ac.uk/riskengine/, accessed 21 June 2011).
12. Hadaegh F et al. Prevalence of coronary heart disease among Tehran adults: Tehran Lipid and Glucose Study. Eastern Mediterranean Health Journal, 2009, 15:157-166.
13. Hadaegh F et al. Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men. Nutrition, Metabolism, and Cardiovascular Diseases, 2009, 19:401-408.
14. Bittner V et al. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2009, 157:548-555.
15. Janghorbani M, Amini M, Tavassoli A. Coronary heart disease in type 2 diabetes mellitus in Isfahan, Iran: prevalence and risk factors. Acta Cardiologica, 2006, 61:13-20.
16. Hadaegh F et al. Glucose intolerance and risk of cardiovascular disease in Iranian men and women: Results of the 7.6-year follow-up of the Tehran Lipid and Glucose Study (TLGS). Journal of Endocrinological Investigation, 2009, 32:724-730.
17. Aghaeishahsavari M et al. Cardiovascular disease risk factors in patients with confrmed cardiovascular disease. Saudi Medical Journal, 2006, 27:1358-1361.
18. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-97
19. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation, 1979, 59:8-13.
20. Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. Journal of the American College of Cardiology, 2000, 36:355-365.
21. Weckbach S et al. Systemic cardiovascular complications in patients with long-standing diabetes mellitus: comprehensive assessment with whole-body magnetic resonance imaging/ magnetic resonance angiography. Investigative Radiology, 2009, 44:242-250.
22. Jurado J et al. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. Journal of the American Academy of Nurse Practitioners, 2009, 21:140-148.
23. Agarwall AK et al. Prevalence of coronary risk factors in type 2 diabetes without manifestation of overt coronary heart disease. Journal of the Association of Physicians of India, 2009, 57:135-142.
24. Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. Journal of the American College of Cardiology, 2007, 49:631-642.
25. Alsaraj F et al. Prevalence of the metabolic syndrome in patients with diabetes mellitus. Irish Journal of Medical Science, 2009, 178(3):309-313.
26. Wong J et al. The metabolic syndrome in type 2 diabetes: when does it matter? Diabetes, Obesity & Metabolism, 2006, 8:690-697.
27. Grundy SM. Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient? American Journal of Medicine, 2007, 120(Suppl. 1):S3-S8.
28. Klausen KP et al. Microalbuminuria and obesity: impact on cardiovascular disease and mortality. Clinical Endocrinology, 2008, 71(1):40-45.
29. Robles NR et al. Riesgo cardiovascular asociado a microalbu-minuria en pacientes diabeticos y en pacientes con hiperten-sion arterial. [Microalbuminuria-related cardiovascular risk in diabetic patients and hypertensive (non diabetic) population]. Medicina Clínica, 2008, 130:206-209.
30. So WY et al. Glomerular fltration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care, 2006, 29:2046-2052.
31. Muntner P et al. Renal insuffciency and subsequent death resulting from cardiovascular disease in the United States. Journal of the American Society of Nephrology, 2002, 13:745-753.
32. Chou CK et al. Analysis of traditional and nontraditional risk factors for peripheral arterial disease in elderly type 2 diabetic patients in Taiwan. Diabetes Research and Clinical Practice, 2008, 81:331-337.
33. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. Journal of the American Medical Association, 2000, 283:2404-2410.
34. Tavil Y et al. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis, 2008, 197:159-163.
35. Wheeler JG et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Medicine, 2005, 2:e76.
36. Hernandez C et al. Prevalence and risk factors accounting for true silent myocardial ischemia: a pilot case-control study comparing type 2 diabetic with non-diabetic control subjects. Cardiovascular Diabetology, 2011, 10(1):9.